Clinical effect of rebacin cervical and vaginal intraepithelial neoplasia

Study on the correlation between high-risk HPV infection and vaginal microflora and cervical high intraepithelial lesions

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057878

Enrollment

Unknown

Registered

2022-03-20

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical and vaginal intraepithelial neoplasia

Interventions

Rebson group:Use rebson

Control group:None

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. High risk HPV infection; 2. No HIV or hepatitis B or C positive or autoimmune disease within six months before sample collection; 3. Follow up and recheck HR-HPV and TCT according to doctor's advice after operation.

Exclusion criteria

Exclusion criteria: 1. Patients who do not use enough (Rebelson recommends using it for at least 20 days a month for 3 consecutive months); 2. Women with basic immune deficiency (such as after chemotherapy); 3. Women with severe heart, lung, liver and kidney dysfunction; 4. Women with drug allergy; 5. Pregnant women or lactating women.

Design outcomes

Primary

Measure	Time frame
HPV;Cytological testing;	—

Countries

China

Contacts

Public Contactyang lin

Second Hospital of Jilin University

linyang@163.com+86 13364312666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026